• About Purdue
    • Ethics and Compliance
    • Locations & Operations
    • Public Policies
  • News & Media
    • New Media Resources
    • Perspectives
    • Media Contacts
  • Careers at Purdue
    • What We Offer You
    • How to Apply
  • Contact Us
Purdue Pharma
  • Healthcare Professionals
    • Purdue Products
    • Patient Savings
    • Ask Purdue Medical
    • Responsible Use of Opioids
    • Clinical Trials
  • Patients & Caregivers
    • Medicines From Purdue
    • Cost Savings
    • Ask Purdue Medical
    • Responsible Use of Opioids
    • Expanded Access Program
  • Addressing the Crisis
    • Public Policies
    • Strong Track Record
    • Ongoing Efforts
    • What We’re Doing Now
    • Perspectives
  • Partnering
  • Corporate Social Responsibility
    • Grants & Giving
Select Page

Purdue Pharma L.P. and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment

Jan 28, 2019 | News

News and Media Alivio to receive up to $14.75 million in upfront and near‐term license exercise payments and is eligible to receive royalties on product sales and over $260 million in research and development milestones STAMFORD, Conn. and BOSTON – Jan 28, 2019 —...

Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain

Jan 7, 2019 | News

News and Media Partners to research novel targets for reductions in pain STAMFORD, Conn., and BEDFORD, Mass., January 7, 2019 – Purdue Pharma L.P. and Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and...

Recent Posts

  • Purdue Pharma Presents Considerations in Opioid Comparator Selection at the College on Problems of Drug Dependence Annual Scientific Meeting
  • Purdue Pharma Announces First Participant Enrolled in Clinical Study Assessing Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose
  • Eisai and Purdue Pharma Announce Buy Out of Purdue’s Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant
  • FDA Grants Competitive Generic Therapy (CGT) Designation to Purdue Pharma’s Investigational Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose
  • Purdue Pharma Announces Landmark Agreement with Oklahoma to Advance the Treatment of Addiction

Archives

  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • September 2018
  • August 2018
  • October 2016
  • March 2016
  • July 2008

Categories

  • News
Purdue, as used in this site, refers to Purdue Pharma L.P. and its subsidiaries, which includes Avrio Health L.P., Imbrium Therapeutics L.P., Adlon Therapeutics L.P. and Greenfield BioVentures L.P., Purdue Pharmaceuticals L.P. and Purdue Pharma Manufacturing L.P.